Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Ital J Gastroenterol Hepatol ; 31(1): 61-5, 1999.
Article in English | MEDLINE | ID: mdl-10091105

ABSTRACT

BACKGROUND: Although the role of cholesterol in tumourigenesis is unclear, it is used by the tumoural cells for biosynthetic processes and for steroid synthesis. AIM: To accertain whether plasma cholesterol levels might be a reliable neoplastic marker of a developing hepatocellular carcinoma in patients with liver cirrhosis. PATIENTS: Plasma cholesterol has been studied in 287 liver cirrhosis patients without hepatocellular carcinoma and in 132 patients with hepatocellular carcinoma. RESULTS: Cholesterol (mean +/- SEM) was higher in hepatocellular carcinoma patients when compared with age-, sex- and Child-Pugh class matched cirrhotic controls. In Child-Pugh class A, B and C with uncomplicated liver cirrhosis these values were, respectively, 142.0 +/- 2.5, 117.3 +/- 2.5, 97.4 +/- 2.9 vs 172.5 +/- 4.7, 163.8 +/- 7.9, 153.5 +/- 8.0 +/- mg/dl in patients with hepatocellular carcinoma (p < 0.001). A significant increase of cholesterol (p < 0.001) has been reported in the patients with liver cirrhosis when complicated by hepatocellular carcinoma and it was not related to cholestasis. CONCLUSIONS: This observation seems to suggest that the enhanced cholesterol biosynthesis by tumoural cells leads to a rise in plasma cholesterol of patients with cancer, and, moreover, that, this increase may be used as a neoplastic marker indicating the development of a tumour in patients with liver cirrhosis.


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Hepatocellular/blood , Cholesterol/blood , Liver Cirrhosis/blood , Liver Neoplasms/blood , Biopsy , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/pathology , Colorimetry , Disease Progression , Female , Follow-Up Studies , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/pathology , Liver Neoplasms/etiology , Liver Neoplasms/pathology , Male , Middle Aged , Prognosis , ROC Curve , Risk Factors
2.
Ital J Gastroenterol Hepatol ; 29(5): 456-8, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9494856

ABSTRACT

The pathogenetic agents which cause encephalopathy due to fulminant hepatic failure are still under debate. Ammonia and benzodiazepine-like compounds are two of the most important agents considered, so far. Herein, we report the levels of benzodiazepine-like compounds in serum and in urine and of venous ammonia measured during the course of the disease (30 days). The patient rapidly developed stage IV encephalopathy with high levels of ammonia and with only a slight increase of benzodiazepine-like compounds. At that moment, the levels of these compounds were similar to those recorded in the blood when the patient regained full consciousness 28 days later. During the course of the disease, there was a 10-fold increase of benzodiazepine-like compounds in serum which was recorded in parallel with an impaired excretion due to oliguria. This observation seems to indicate that encephalopathy may develop in the absence of significantly increased levels of these compounds and that their episodic increase during fulminant hepatic failure may be an epiphenomenon linked with several factors such as impaired renal function.


Subject(s)
Benzodiazepines/metabolism , Hepatic Encephalopathy/metabolism , Adult , Ammonia/blood , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...